The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...

GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...

Drugmaker GSK said on Friday that the US Food and Drug Administration had approved its Blenrep asset in combination with ...

The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...

FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...